Hematology

Learn how talquetamab combinations significantly improved survival and response rates in the Phase 3 MonumenTAL-3 trial.

Learn how a Phase 3 trial shows mitapivat significantly improves anaemia and haemolysis in sickle cell disease.

Learn why young patients with CML show higher rates of first-line TKI resistance than older patients.

Read more about how salvage allo-HSCT improved survival in relapsed/refractory B-ALL patients after CAR-T therapy failure.

People living with HIV face significantly longer travel times and reduced access to CAR-T clinical trials for non-Hodgkin lymphoma, with disparities most pronounced in the southern United States.

The 2024 EBMT activity survey showed record allogeneic transplant numbers and continued expansion of CAR T therapy across Europe and affiliated countries.

Elevated von Willebrand factor and factor VIII levels demonstrated diagnostic potential and disease activity associations in chronic Graft-versus-Host Disease.

A venetoclax-based AML regimen produced high remission rates and prolonged survival in older or unfit patients with newly diagnosed acute myeloid leukaemia.